244 related articles for article (PubMed ID: 37283638)
21. Preventing monkeypox outbreaks: Focus on diagnosis, care, treatment, and vaccination.
Ghaseminia M
J Clin Transl Sci; 2023; 7(1):e60. PubMed ID: 37008622
[TBL] [Abstract][Full Text] [Related]
22. Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study.
McLean J; Stoeckle K; Huang S; Berardi J; Gray B; Glesby MJ; Zucker J
Ann Intern Med; 2023 May; 176(5):642-648. PubMed ID: 37126820
[TBL] [Abstract][Full Text] [Related]
23. Identifying potential monkeypox virus inhibitors: an
Ashley CN; Broni E; Wood CM; Okuneye T; Ojukwu MT; Dong Q; Gallagher C; Miller WA
Front Cell Infect Microbiol; 2024; 14():1351737. PubMed ID: 38500508
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.
De Clercq E; Jiang Y; Li G
Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022
[TBL] [Abstract][Full Text] [Related]
25. Monkeypox treatment: Current evidence and future perspectives.
Khani E; Afsharirad B; Entezari-Maleki T
J Med Virol; 2023 Jan; 95(1):e28229. PubMed ID: 36253931
[TBL] [Abstract][Full Text] [Related]
26. Clinical Strategies and Therapeutics for Human Monkeypox Virus: A Revised Perspective on Recent Outbreaks.
Ghosh N; Chacko L; Vallamkondu J; Banerjee T; Sarkar C; Singh B; Kalra RS; Bhatti JS; Kandimalla R; Dewanjee S
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515218
[TBL] [Abstract][Full Text] [Related]
27. Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies.
Rabaan AA; Abas AH; Tallei TE; Al-Zaher MA; Al-Sheef NM; Fatimawali ; Al-Nass EZ; Al-Ebrahim EA; Effendi Y; Idroes R; Alhabib MF; Al-Fheid HA; Adam AA; Bin Emran T
J Med Virol; 2023 Jan; 95(1):e28306. PubMed ID: 36372558
[TBL] [Abstract][Full Text] [Related]
28. Mpox and HIV: a Narrative Review.
Saldana CS; Kelley CF; Aldred BM; Cantos VD
Curr HIV/AIDS Rep; 2023 Aug; 20(4):261-269. PubMed ID: 37178205
[TBL] [Abstract][Full Text] [Related]
29. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
[TBL] [Abstract][Full Text] [Related]
30. Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.
Akazawa D; Ohashi H; Hishiki T; Morita T; Iwanami S; Kim KS; Jeong YD; Park ES; Kataoka M; Shionoya K; Mifune J; Tsuchimoto K; Ojima S; Azam AH; Nakajima S; Park H; Yoshikawa T; Shimojima M; Kiga K; Iwami S; Maeda K; Suzuki T; Ebihara H; Takahashi Y; Watashi K
J Infect Dis; 2023 Aug; 228(5):591-603. PubMed ID: 36892247
[TBL] [Abstract][Full Text] [Related]
31. Lack of clinical evidence of antiviral therapy for human monkeypox: A scoping review.
Kuroda N; Shimizu T; Hirano D; Ishikane M; Kataoka Y
J Infect Chemother; 2023 Feb; 29(2):228-231. PubMed ID: 36283609
[TBL] [Abstract][Full Text] [Related]
32. Monkeypox: Virology, Pathophysiology, Clinical Characteristics, Epidemiology, Vaccines, Diagnosis, and Treatments.
Soheili M; Nasseri S; Afraie M; Khateri S; Moradi Y; Mahdavi Mortazavi SM; Gilzad-Kohan H
J Pharm Pharm Sci; 2022; 25():297-322. PubMed ID: 36130588
[TBL] [Abstract][Full Text] [Related]
33. A brief on new waves of monkeypox and vaccines and antiviral drugs for monkeypox.
Hung YP; Lee CC; Lee JC; Chiu CW; Hsueh PR; Ko WC
J Microbiol Immunol Infect; 2022 Oct; 55(5):795-802. PubMed ID: 36115792
[TBL] [Abstract][Full Text] [Related]
34. VP37 Protein Inhibitors for Mpox Treatment: Highlights on Recent Advances, Patent Literature, and Future Directions.
Hudu SA; Alshrari AS; Al Qtaitat A; Imran M
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189724
[TBL] [Abstract][Full Text] [Related]
35. Insights into the Transmission, Host Range, Genomics, Vaccination, and Current Epidemiology of the Monkeypox Virus.
Araf Y; Nipa JF; Naher S; Maliha ST; Rahman H; Arafat KI; Munif MR; Uddin MJ; Jeba N; Saha S; Zhai J; Hasan SMN; Xue M; Hossain MG; Zheng C
Vet Med Int; 2024; 2024():8839830. PubMed ID: 38836166
[TBL] [Abstract][Full Text] [Related]
36. Prolonged Mpox Disease in People With Advanced HIV: Characterization of Mpox Skin Lesions.
O'Shea J; Zucker J; Stampfer S; Cash-Goldwasser S; Minhaj FS; Dretler A; Cheeley J; Chaudhuri S; Gallitano SM; Gunaratne S; Parkinson M; Epling B; Morcock DR; Sereti I; Deleage C
J Infect Dis; 2024 Mar; 229(Supplement_2):S243-S248. PubMed ID: 38019806
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat.
Nunes DDS; Higa LM; Oliveira RL; da Costa LC; Bomfim LM; Gonçalves CCA; Mariani D; Hruby DE; Voloch CM; Castiñeiras TMPP; Tanuri A; Damaso CR
Mem Inst Oswaldo Cruz; 2023; 118():e230056. PubMed ID: 37436275
[TBL] [Abstract][Full Text] [Related]
38. Monkeypox and drug repurposing: seven potential antivirals to combat the viral disease.
Varghese R; Patel P; Kumar D; Sharma R
Rev Environ Health; 2023 Feb; ():. PubMed ID: 36809250
[TBL] [Abstract][Full Text] [Related]
39. Metabolism Pathways of Major Therapeutics for Treating Monkeypox Mono- and Co-infection with Human Immunodeficient Virus or SARS-CoV-2.
Yan D; Yan B
Curr Drug Metab; 2023; 24(4):240-249. PubMed ID: 37287302
[TBL] [Abstract][Full Text] [Related]
40. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.
Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
